Abivax S.A.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abivax S.A. (ABVX) is a clinical-stage biotechnology company that develops therapeutics harnessing the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124, to stabilize immune responses in patients with chronic inflammatory diseases; its lead product candidate, obefazimod (formerly ABX464), is an investigational oral small molecule in Phase 3 clinical trials for moderately to severely active ulcerative colitis under the ABTECT program and in Phase 2 development for Crohn's disease under the ENHANCE-CD program; the company also maintains a proprietary chemical library for discovering follow-on drug candidates targeting additional inflammatory indications. Founded in 2013 and headquartered in Paris, France, with research and development facilities in Montpellier, France, and a U.S. office in Waltham, Massachusetts, Abivax operates globally across North America, Europe, Latin America, and Asia Pacific through its clinical trial network spanning over 600 sites in 36 countries. In recent developments, Abivax announced positive top-line results from the 8-week induction trials of obefazimod in ulcerative colitis in Q3 2025, with 44-week maintenance data expected in Q2 2026; completed a $747.5 million public offering in July 2025 to extend its cash runway into Q4 2027; initiated patient enrollment for the ENHANCE-CD Crohn's disease trial in Q3 2024 with data anticipated in 2H 2026; and reduced debt through conversions including EUR 21.9 million from Heights Capital Management post-H1 2025.
Company News
Cedar Grove Capital Q3 2026 Portfolio Update
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Brokerages
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
4 Biotech Stocks to Watch as Potential Takeover Targets
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
3 Soaring Stocks That May Have More Upside Ahead
Abivax: Wall Street Catches Up to the Data
Abivax Announces Closing of $920 Million Public Offering
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares